Abstract: Provided are a fisheye camera calibration system, method and an electronic device. The system includes a hemispherical target, a fisheye camera and an electronic device. The hemispherical target includes a hemispherical inner surface and multiple markers provided on the hemispherical inner surface. The fisheye camera is used for photographing the hemispherical target and acquiring a target image, where the hemispherical target and the multiple markers provided on the hemispherical inner surface are captured in the target image. The electronic device is used for acquiring initial values of k1, k2, k3, k4, k5, u0, v0, mu and mv, and using a Levenberg-Marquardt algorithm to optimize the initial values of k1, k2, k3, k4, k5, u0, v0, mu and mv, so as to determine imaging model parameters of the fisheye camera.

Abstract: Provided are a fisheye camera calibration system, method and an electronic device. The system includes a polyhedral target, a fisheye camera and an electronic device. The polyhedral target includes an inner surface and multiple markers provided on the inner surface, and the inner surface is composed of multiple hexagonal and pentagonal planes. The fisheye camera is used for photographing the polyhedral target to collect a target image, where the polyhedral target and the multiple markers provided on the inner surface of the polyhedral target are captured in the target image. The electronic device is used for acquiring initial values of k1, k2, k3, k4, k5, u0, v0, mu, mv, Tj and Rj, and using a Levenberg-Marquardt algorithm to optimize the initial values of k1, k2, k3, k4, k5, u0, v0, mu, mv, Tj and Rj so as to determine imaging model parameters of the fisheye camera.

Abstract: Provided are a fisheye camera calibration system, method and an electronic device. The system includes a polyhedral target, a fisheye camera and an electronic device. The polyhedral target includes an inner surface and multiple markers provided on the inner surface, and the inner surface is composed of multiple hexagonal and pentagonal planes. The fisheye camera is used for photographing the polyhedral target to collect a target image, where the polyhedral target and the multiple markers provided on the inner surface of the polyhedral target are captured in the target image. The electronic device is used for acquiring initial values of k1, k2, k3, k4, k5, u0, v0, mu, mv, Tj and Rj, and using a Levenberg-Marquardt algorithm to optimize the initial values of k1, k2, k3, k4, k5, u0, v0, mu, mv, Tj and Rj so as to determine imaging model parameters of the fisheye camera.

Abstract: Provided are a fisheye camera calibration system, method and an electronic device. The system includes a hemispherical target, a fisheye camera and an electronic device. The hemispherical target includes a hemispherical inner surface and multiple markers provided on the hemispherical inner surface. The fisheye camera is used for photographing the hemispherical target and acquiring a target image, where the hemispherical target and the multiple markers provided on the hemispherical inner surface are captured in the target image. The electronic device is used for acquiring initial values of k1, k2, k3, k4, k5, u0, v0, mu and mv, and using a Levenberg-Marquardt algorithm to optimize the initial values of k1, k2, k3, k4, k5, u0, v0, mu and mv, so as to determine imaging model parameters of the fisheye camera.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Abstract: The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.

Abstract: The present invention relates to pharmaceutical compositions comprising a topoisomerase I inhibitor including, but not limited to, a camptothecin derivative.

Abstract: A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes and/or liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components. After a desired liposome biodistribution is achieved, the affinity agent binds to the target surface and helps internalize the liposomes.

Abstract: The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN-38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN-38 into complexes and are capable of solubilizing relatively high concentrations of SN-38.

Abstract: Delivering therapeutic amounts of irinotecan remains limited due to its highly water insoluble properties. This invention overcomes this limitation by presenting a novel method of preparing liposomal irinotecan by first inactivating irinotecan prior to liposome formation and then subsequently activating the irinotecan by lowering the pH of the lipid composition to an acidic pH of less than about 3.5, such as between 1.5-3.0 or about 2.

Abstract: The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.

Abstract: The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped gemcitabine in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds including cardiolipin.

Abstract: SN38, camptothecin derivatives are poorly water soluble, highly lipophilic camptothecin derivatives and are very active against a variety of human cancers. Because of their very poor water solubility, SN38 has not been used to treat human patients with cancer due to the inability to administer sufficient quantities of dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable SN38 liposome complex formulation for the direct administration of the formulation to human patients with cancer. The claimed invention also describes the methods to prepare liposomal SN38 complexes and antitumor compositions of liposomal SN38 complexes to allow the administration in sufficient amounts to treat various types of cancer and as antiviral agents. This invention is also directed to injectable sterile solutions, antitumor compositions, liposomes.

Abstract: The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped vinorelbine in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds and cardiolipin. The liposomes of the present invention can be either multilamellar vesicles or unilamellar vesicles, as desired.

Abstract: The present invention is for novel compositions and methods for treating diseases caused by cellular proliferation, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include SN-38 lipid complexes in which the complexes can contain any of a variety of neutral or charged lipids and, desirably, cardiolipin. The compositions are capable of efficiently incorporating SN-38 into complexes and are capable of solubilizing relatively high concentrations of SN-38.